Efficacy and safety of laquinimod versus placebo in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials
Objective To investigate the safety and efficacy of laquinimod in treating relapsing-remitting multiple sclerosis (RRMS). Methods An extensive electronic search was conducted across PubMed, Embase, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov to identify suitable studies. Risk of...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-02-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605241311437 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206299097300992 |
|---|---|
| author | Malik Waleed Zeb Khan Aizaz Ali Amna Hussain Safeena Khan Ammara Tahir Muhammad Haris Khan Touba Azeem Abdul Moeez Arysha Monis Aban Masaud Mian Fazia Khattak Moosa Ali Jibran Ikram |
| author_facet | Malik Waleed Zeb Khan Aizaz Ali Amna Hussain Safeena Khan Ammara Tahir Muhammad Haris Khan Touba Azeem Abdul Moeez Arysha Monis Aban Masaud Mian Fazia Khattak Moosa Ali Jibran Ikram |
| author_sort | Malik Waleed Zeb Khan |
| collection | DOAJ |
| description | Objective To investigate the safety and efficacy of laquinimod in treating relapsing-remitting multiple sclerosis (RRMS). Methods An extensive electronic search was conducted across PubMed, Embase, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov to identify suitable studies. Risk of bias was assessed using Cochrane’s Risk of Bias tool. Statistical analysis was performed using RevMan 5.4.1. Results The meta-analysis of four randomized controlled trials including 3665 patients found that laquinimod significantly reduced the annualized relapse rate compared with placebo (mean difference = −0.08, 95% confidence interval [CI] = −0.12, −0.04, I 2 = 0%). For disability progression confirmed at 3 months, laquinimod provided a significant advantage over placebo (hazard ratio [HR] = 0.75, 95% CI = 0.59, 0.96, I 2 = 25%), whereas no benefit was achieved at 6 months (HR = 0.69, 95% CI = 0.45, 1.06, I 2 = 66%). Laquinimod was also significantly better than placebo in maintaining a relapse-free status (risk ratio [RR] = 1.14 95% CI = 1.06, 1.22, I 2 = 10%). Laquinimod had a comparable safety profile as placebo (RR = 1.06, 95% CI = 0.81, 1.39, I 2 = 33%). Conclusions These findings support the efficacy of laquinimod in managing RRMS but necessitate careful monitoring during treatment. |
| format | Article |
| id | doaj-art-4a430041171d4a3391f40613853963f7 |
| institution | Kabale University |
| issn | 1473-2300 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of International Medical Research |
| spelling | doaj-art-4a430041171d4a3391f40613853963f72025-02-07T11:03:34ZengSAGE PublishingJournal of International Medical Research1473-23002025-02-015310.1177/03000605241311437Efficacy and safety of laquinimod versus placebo in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of randomized controlled trialsMalik Waleed Zeb KhanAizaz AliAmna HussainSafeena KhanAmmara TahirMuhammad Haris KhanTouba AzeemAbdul MoeezArysha MonisAban Masaud MianFazia KhattakMoosa AliJibran IkramObjective To investigate the safety and efficacy of laquinimod in treating relapsing-remitting multiple sclerosis (RRMS). Methods An extensive electronic search was conducted across PubMed, Embase, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov to identify suitable studies. Risk of bias was assessed using Cochrane’s Risk of Bias tool. Statistical analysis was performed using RevMan 5.4.1. Results The meta-analysis of four randomized controlled trials including 3665 patients found that laquinimod significantly reduced the annualized relapse rate compared with placebo (mean difference = −0.08, 95% confidence interval [CI] = −0.12, −0.04, I 2 = 0%). For disability progression confirmed at 3 months, laquinimod provided a significant advantage over placebo (hazard ratio [HR] = 0.75, 95% CI = 0.59, 0.96, I 2 = 25%), whereas no benefit was achieved at 6 months (HR = 0.69, 95% CI = 0.45, 1.06, I 2 = 66%). Laquinimod was also significantly better than placebo in maintaining a relapse-free status (risk ratio [RR] = 1.14 95% CI = 1.06, 1.22, I 2 = 10%). Laquinimod had a comparable safety profile as placebo (RR = 1.06, 95% CI = 0.81, 1.39, I 2 = 33%). Conclusions These findings support the efficacy of laquinimod in managing RRMS but necessitate careful monitoring during treatment.https://doi.org/10.1177/03000605241311437 |
| spellingShingle | Malik Waleed Zeb Khan Aizaz Ali Amna Hussain Safeena Khan Ammara Tahir Muhammad Haris Khan Touba Azeem Abdul Moeez Arysha Monis Aban Masaud Mian Fazia Khattak Moosa Ali Jibran Ikram Efficacy and safety of laquinimod versus placebo in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials Journal of International Medical Research |
| title | Efficacy and safety of laquinimod versus placebo in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials |
| title_full | Efficacy and safety of laquinimod versus placebo in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials |
| title_fullStr | Efficacy and safety of laquinimod versus placebo in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials |
| title_full_unstemmed | Efficacy and safety of laquinimod versus placebo in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials |
| title_short | Efficacy and safety of laquinimod versus placebo in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials |
| title_sort | efficacy and safety of laquinimod versus placebo in relapsing remitting multiple sclerosis a systematic review and meta analysis of randomized controlled trials |
| url | https://doi.org/10.1177/03000605241311437 |
| work_keys_str_mv | AT malikwaleedzebkhan efficacyandsafetyoflaquinimodversusplaceboinrelapsingremittingmultiplesclerosisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT aizazali efficacyandsafetyoflaquinimodversusplaceboinrelapsingremittingmultiplesclerosisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT amnahussain efficacyandsafetyoflaquinimodversusplaceboinrelapsingremittingmultiplesclerosisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT safeenakhan efficacyandsafetyoflaquinimodversusplaceboinrelapsingremittingmultiplesclerosisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT ammaratahir efficacyandsafetyoflaquinimodversusplaceboinrelapsingremittingmultiplesclerosisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT muhammadhariskhan efficacyandsafetyoflaquinimodversusplaceboinrelapsingremittingmultiplesclerosisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT toubaazeem efficacyandsafetyoflaquinimodversusplaceboinrelapsingremittingmultiplesclerosisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT abdulmoeez efficacyandsafetyoflaquinimodversusplaceboinrelapsingremittingmultiplesclerosisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT aryshamonis efficacyandsafetyoflaquinimodversusplaceboinrelapsingremittingmultiplesclerosisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT abanmasaudmian efficacyandsafetyoflaquinimodversusplaceboinrelapsingremittingmultiplesclerosisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT faziakhattak efficacyandsafetyoflaquinimodversusplaceboinrelapsingremittingmultiplesclerosisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT moosaali efficacyandsafetyoflaquinimodversusplaceboinrelapsingremittingmultiplesclerosisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT jibranikram efficacyandsafetyoflaquinimodversusplaceboinrelapsingremittingmultiplesclerosisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |